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Abstract
Background: Weight gain after breast cancer has been associated with recurrence and mortality. We therefore
examined factors associated with ‡5% weight gain over 2-year follow-up of a cohort of newly diagnosed early-
stage invasive breast cancer (EIBC) and ductal carcinoma in situ (DCIS) patients and age-matched controls
without a breast cancer history.
Materials and Methods: We interviewed participants 4–6 weeks after definitive surgical treatment (patients) or a
negative/benign screening mammogram (controls). Multivariable logistic regression models were used to identify
socioeconomic, psychosocial, and treatment factors associated with ‡5% weight gain over 2-year follow-up.
Results: Overall, 88 (24%) of 362 EIBC patients, 31 (17%) of 178 DCIS patients, and 82 (15%) of 541 controls
had ‡5% weight gain during follow-up. EIBC patients were more likely to experience ‡5% weight gain than
DCIS patients (Odds ratio [OR] = 2.16; 95% confidence interval [95% CI] = 1.19–3.95) and controls (OR = 1.76;
95% CI = 1.23–2.51). Among EIBC patients, older patients (OR = 0.96; 95% CI = 0.93–0.99), patients who
underwent endocrine therapy (OR = 0.43; 95% CI = 0.19–0.95), smokers (OR = 0.35; 95% CI = 0.14–0.86), and
African Americans (OR = 0.23; 95% CI = 0.09–0.58) were less likely to have ‡5% weight gain than their
respective counterparts. Among DCIS patients, older patients (OR = 0.94; 95% CI = 0.89–0.99) were less
likely to have ‡5% weight gain. Among controls, smokers were more likely to have ‡5% weight gain
(OR = 3.03; 95% CI = 1.49–6.17).
Conclusions: EIBC patients were more likely than DCIS patients and controls to experience ‡5% weight gain
over follow-up. Studies are necessary to elucidate mechanisms of weight gain in early-stage breast cancer
survivors.
Keywords: breast cancer, weight gain, ductal carcinoma in situ (DCIS), early-stage breast cancer (EIBC),
estrogen receptor
Introduction
Weight gain is common following breast cancer treat-ment.1 Weight gain in breast cancer patients is of
particular concern because of its impact on prognosis, self-
image, and quality of life.2 Prior studies have shown that the
onset of menopause and the receipt of adjuvant chemother-
apy are risk factors for weight gain in breast cancer patients,
with the most significant weight gain observed in women
undergoing cytotoxic therapies and women treated with
both chemotherapy and hormonal treatment.2–4 Proposed
mechanisms of breast cancer-related weight gain include
chemotherapy-related amenorrhea and insulin resistance.5,6
In addition, declines in physical activity or inactivity after
diagnosis may also contribute significantly to weight gain.5,6
As studies have shown that patients are unlikely to return to
prediagnosis weight after gaining weight,5,7 it has become
increasingly important to identify at-risk patients and po-
tential targets for interventions to combat weight gain in
breast cancer patients.
1Brown School, Washington University in St. Louis, St. Louis, Missouri.
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Patients with incident ductal carcinoma in situ (DCIS)
have a clinical diagnosis distinct from patients with early-
stage invasive breast cancer (EIBC). DCIS patients also
have a much better prognosis than EIBC patients, irrespective
of treatment administered.8,9 Although some longitudinal
studies have compared weight gain in breast cancer patients
and women without a history of breast cancer, results are
mixed,3,10,11 and few have evaluated whether there are dif-
ferences in weight gain between DCIS and EIBC patients.
We hypothesize that EIBC patients would gain more weight
over time than both DCIS patients and cancer-free women.
Therefore, the purpose of this study was to (a) examine dif-
ferences in weight gain over 2 years in EIBC patients, DCIS
patients, and an age-matched control group of women with-
out a history of breast cancer, and (b) to identify socio-
demographic, psychosocial, and treatment factors associated
with weight gain within these three groups. Identifying risk
factors within each of the three groups of participants will
allow for the development of strategies to minimize weight
gain after a breast cancer diagnosis.
Materials and Methods
Participants
We conducted a secondary analysis of data collected for a
study which was designed to examine changes in quality of
life in a cohort of first primary DCIS (stage 0) and EIBC
(stages 1–2A) cases and of age-matched women without a
history of any breast cancer.12 Between October 2003 and
June 2007, study participants were recruited from two sites in
St. Louis, Missouri: Siteman Cancer Center at Barnes-Jewish
Hospital and Washington University School of Medicine and
Saint Louis University School of Medicine. Breast cancer
stage was determined by surgical pathology. We included
women at least 40 years of age without a breast cancer his-
tory; we excluded patients who had received neoadjuvant
chemotherapy and who did not speak English. Age-matched
controls were identified within 2 weeks of a negative or be-
nign screening mammogram. The study enrolled a total of
365 EIBC patients, 184 DCIS patients, and 547 controls.
Participants completed four, 45–60 minutes computer-
assisted telephone interviews at 4–6 weeks after definitive
surgical treatment (patients) or screening mammogram (con-
trols) and then at 6-, 12-, and 24-month follow-up. Detailed
recruitment and interview procedures have been published
previously.12,13 Informed consent was obtained from all par-
ticipants, and the study was approved by the Institutional
Review Boards at both institutions.
Measures
For this analysis, the primary outcome of interest was ‡5%
weight gain after 2 years of follow-up. At each interview,
weight was ascertained using a question from the CDC Be-
havioral Risk Factor Surveillance System.14 Study partici-
pants were asked ‘‘About how much do you weigh without
shoes?’’ Weight gain was calculated using percent weight
change ([24-month weight minus baseline weight]/baseline
weight) *100, and analyzed as a dichotomous outcome: ‡5%
versus <5% weight gain. Weight gain of ‡5% is considered
clinically significant,15,16 and this cut-point has been widely
used in previous studies of weight gain and health outcomes
in breast cancer survivors.7,17
Sociodemographic information collected from interviews
included age at enrollment, race, marital status, education,
health insurance status, employment status, household in-
come, menopausal status at enrollment, body mass index
(BMI), and smoking status. Using a validated questionnaire
based on the Charlson comorbidity index, we determined the
severity of comorbidity.18,19 Social support was assessed
using the Medical Outcomes Study (MOS) Social Support
Survey, with higher scores indicating more social support.20
Elevated depressed mood was defined as a Center for Epi-
demiologic Studies-Depression score of 16 or higher.21,22 We
used the eight subscales (physical functioning, role limita-
tions due to physical problems, role limitations due to emo-
tional health, vitality, emotional well-being, social functioning,
pain, and general health) of the RAND 36-Item Health Survey
subscales to evaluate quality of life.23–25 Patients’ clinical
data obtained from medical records included estrogen receptor
(ER) status (positive or negative), cancer stage, surgery type
(lumpectomy or mastectomy), and receipt of adjuvant en-
docrine therapy, adjuvant radiation or chemotherapy during
the study. We evaluated surgical side effects severity using a
list of eight commonly reported side effects derived from the
literature, which we previously validated.13
Statistical analyses
Chi-square and Kruskal–Wallis tests were used to compare
baseline characteristics across the three diagnostic groups:
EIBC, DCIS, and controls. Multivariable logistic regression
was first used to evaluate the association between diagnos-
tic group and ‡5% weight gain, estimating adjusted odds
ratios (ORs) and 95% confidence intervals (CIs) for ‡5%
weight gain for each patient group relative to controls. Po-
tential confounders included the sociodemographic factors,
psychosocial factors and treatment such as radiation, che-
motherapy, and endocrine therapy. We used directed acyclic
graphs to determine the minimally sufficient set of con-
founders.26,27 Thus, the adjusted models included BMI (ob-
ese [‡30 kg/m2] and overweight [25 to <30 kg/m2], each
vs. underweight/normal weight [<25 kg/m2]), race (African
American vs. white, excluding 13 participants from other
racial/ethnic groups because of small numbers), marital sta-
tus (married/partnered vs. not married/not partnered), edu-
cation (high school graduate or less education vs. more than
high school), annual household income (<$50,000 and re-
fused to answer, each vs. ‡ $50,000), smoking status (current,
former, vs. never), age at enrollment, and the vitality sub-
scale of the RAND SF-36 Health Survey (hereafter referred
to as vitality), an established measure of energy/fatigue, with
higher scores indicating more energy and less fatigue (range
0–100).
We further evaluated weight gain among the three diag-
nostic groups (EIBC, DCIS and controls) separately using
stratified logistic regression models to identify independent
predictors within each group. For the patient (EIBC and
DCIS) groups, models were further adjusted for treatment
received (endocrine therapy, radiation, and chemotherapy).
Weight gain in postmenopausal women is a risk factor for
cancer-related outcomes.28,29 Thus, we further stratified EIBC
models by menopausal status to investigate potential differences















































Table 1. Characteristics of the Study Sample by Diagnostic Group
EIBC DCIS Control
paN = 362 N = 178 N = 541
Median (IQR)
Age 58 (51, 66) 55 (49, 64) 55 (49, 64) 0.04
Vitality 52.5 (35, 70) 55 (40, 75) 65 (50, 80) <0.001
N (%)b
Weight change 0.002
Weight gain ‡5% body weight 88 (24.3) 31 (17.4) 82 (15.2)
Weight gain <5% body weight 274 (75.7) 147 (82.6) 459 (84.8)
BMI 0.87
Obese (‡30 kg/m2) 121 (33.4) 63 (35.4) 171 (31.6)
Overweight (25 to <30 kg/m2) 113 (31.2) 53 (29.8) 165 (30.5)
Normal weight (<25 kg/m2) 128 (35.4) 62 (34.8) 205 (37.9)
Race 0.01
African American 69 (19.1) 32 (18.0) 143 (26.4)
White 293 (80.9) 146 (82.0) 398 (73.6)
Marital status 0.59
Married 214 (59.1) 112 (62.9) 336 (62.1)
Not married 148 (40.9) 66 (37.1) 205 (37.9)
Education 0.04
£High school 116 (32.0) 52 (29.2) 135 (25.0)
>High school 246 (68.0) 126 (70.8) 405 (75.0)
Income 0.03
<$50,000 183 (50.6) 84 (47.2) 223 (41.2)
Refused 30 (8.3) 12 (6.7) 36 (6.7)
‡$50,000 149 (41.2) 82 (46.1) 282 (52.1)
Smoking status 0.47
Current smoker 52 (14.4) 18 (10.1) 64 (11.8)
Former smoker 111 (30.7) 63 (35.4) 189 (34.9)
Never smoker 199 (55.0) 97 (54.5) 288 (53.2)
Menopausal statusc 0.17
Premenopausal 88 (24.3) 54 (30.3) 147 (27.2)
Postmenopausal 273 (75.7) 122 (69.3) 393 (72.8)
Surgery type 0.16
Breast-conserving surgery 242 (66.9) 108 (60.7) —
Mastectomy 120 (33.2) 70 (39.3) —
Estrogen receptor statusd <0.0001
ER-positive 282 (80.1) 85 (75.9) —
ER-negative 70 (19.9) 27 (24.1) —
Radiation 0.02
Yes 243 (67.1) 101 (56.7) —
No 119 (32.9) 77 (42.3) —
Chemotherapy and Endocrine therapye <0.0001
Both 80 (22.2) 0 (0) —
Chemotherapy only 54 (15.0) 0 (0) —
Endocrine therapy only 182 (50.4) 77 (44.3) —
No 45 (12.5) 97 (55.8) —
ap value derived from Kruskal–Wallis test for continuous variables and Chi-square tests for categorical variables. Bold type indicates
statistical significance at p < 0.05.
bPercentages may not sum up to 100% due to rounding.
cData for menopausal status were missing for four patients (one DCIS, one EIBC, and two Controls).
dData for estrogen receptor status were missing for 76 patients (66 DCIS and 10 EIBC).
eData for endocrine therapy or chemotherapy were missing for five patients (four DCIS and one EIBC).
















































in associations with weight gain as reported in previous
studies.30–32 Finally, sensitivity analyses were performed
by excluding patients who experienced ‡5% weight loss
between baseline and 2 years. Stata version 14 was used for
all statistical analyses. Two-tailed tests of significance at
p < 0.05 were considered significant.
Results
Characteristics of the study sample
The sample’s baseline characteristics are described in
Table 1. Median age at enrollment for EIBC patients was
higher than for DCIS patients and controls, while baseline
vitality scores were lower for EIBC patients than for DCIS
patients and controls. In addition, greater proportions of
EIBC patients reported £ high school education and annual
household income <$50,000 compared with DCIS patients
and controls. A higher percentage of DCIS patients reported
lower education and lower household income than the control
group. EIBC patients (80%) were more likely to have ER-
positive tumors than DCIS patients (76%). A greater pro-
portion of EIBC patients (67%) received radiation compared
with DCIS patients (57%). Approximately 14% of EIBC
patients received only chemotherapy treatment, whereas DCIS
patients did not receive chemotherapy. BMI, marital status,
smoking status, and menopausal status did not differ signif-
icantly among the three diagnostic groups at baseline.
Weight gain among EIBC patients,
DCIS patients, and controls
At the 2-year follow-up, *24% of EIBC patients, 17% of
DCIS patients, and 15% of controls gained ‡5% body weight
during follow-up (Fig. 1). In multivariable models, EIBC
patients were 1.8 times more likely to experience ‡5% weight
gain than controls (Table 2). In addition, EIBC patients were
2.2 times more likely to experience ‡5% weight gain com-
pared with DCIS patients (OR = 2.16, 95% CI = 1.19–3.95).
Patients who underwent radiation were more likely to expe-
rience ‡5% weight gain than those who did not (OR = 1.74,
95% CI = 1.06–2.87). African American women were 55%
less likely to have ‡5% weight gain than white women
(Table 2). Results of the sensitivity analysis excluding pa-
tients who experienced ‡5% weight loss were robust and
consistent with the results from the primary model. (Sup-
plementary Table 1).
As shown in Table 3, among EIBC patients, older patients,
African American (vs. white) patients, and current (vs. never)
smokers were less likely to have ‡5% weight gain. EIBC
patients who underwent endocrine therapy were also less
likely to experience ‡5% weight gain. Among DCIS patients,
age was inversely associated with weight gain. Among con-
trols, current (vs. never) smokers were three times more
likely to gain weight than never smokers. For EIBC patients,
sensitivity analysis further confirmed the effects of age,
race, and endocrine therapy on weight gain (Supplementary
Table 2).
Menopausal status and weight gain in EIBC patients
Approximately 17% (n = 62) of EIBC patients changed
from pre- to postmenopausal over the follow-up period;
22 (35%) of these patients experienced ‡5% weight gain.
Women who became postmenopausal during follow-up
were twice as likely to experience ‡5% weight gain as wo-
men who were postmenopausal at study onset (OR = 2.04,
95% CI = 1.04–4.01, data not shown). Because of small
numbers, we were unable to further evaluate factors asso-
ciated with weight gain among premenopausal women and
women who experienced menopause during the study period.
Among postmenopausal EIBC patients, African American
(vs. white) women were less likely to have ‡5% weight gain,
FIG. 1. Proportion of
Study Population with ‡5%
Weight Gain by Diagnostic
Group.















































and patients who underwent endocrine therapy were less
likely to have ‡5% weight gain (Table 4). In addition, lower
(<$50,000) income was associated with an increased likeli-
hood of ‡5% weight gain. Sensitivity analysis confirmed the
effects of race, income, and endocrine therapy for postmen-
opausal EIBC patients (Supplementary Table 3).
Discussion
In this 2-year study of newly diagnosed early-stage breast
cancer patients and age-matched controls, we found that
EIBC patients were 1.8 times more likely than controls
without a history of breast cancer and twice as likely as DCIS
patients to report ‡5% weight gain. There was no significant
difference in likelihood of ‡5% weight gain between DCIS
patients and controls, and vitality was not associated with
weight gain. We also observed that African American par-
ticipants were 55% less likely to report ‡5% weight gain
over the 2-year follow-up period than white participants. We
discuss our findings in the context of the literature to date
regarding differences in weight gain by diagnostic group,
race/ethnicity, smoking, and treatment.
Table 2. Logistic Regression for the Relationship Between Selected













Age, median (IQR) 55 (49, 62) 57 (50, 65.5) 0.97 (0.95–0.99) 0.96 (0.93–0.98)
Vitality, median (IQR) 55 (40, 75) 60 (45, 75) 1.00 (0.99–1.01) 1.00 (0.99–1.01)
N (%)c
Diagnostic group
EIBC 88 (43.8) 274 (31.1) 1.76 (1.23–2.51) 2.16 (1.19–3.95)
DCIS 31 (15.4) 147 (16.7) 1.08 (0.68–1.72) Reference
Control 82 (40.8) 459 (52.2) Reference —
BMI
Obese (‡30 kg/m2) 66 (32.8) 289 (32.8) 1.12 (0.75–1.65) 0.88 (0.52–1.50)
Overweight (25 to <30 kg/m2) 61 (30.4) 270 (30.7) 1.13 (0.77–1.67) 1.00 (0.58–1.73)
Normal weight (<25 kg/m2) 74 (36.8) 321 (36.5) Reference Reference
Race
African American 30 (14.9) 214 (24.3) 0.45 (0.28–0.72) 0.28 (0.13–0.60)
White 171 (85.1) 666 (75.7) Reference Reference
Marital status
Married 119 (59.2) 543 (61.7) 0.78 (0.53–1.15) 0.87 (0.51–1.50)
Not married 82 (40.8) 337 (38.3) Reference Reference
Education
£High school 52 (25.9) 251 (28.6) 0.93 (0.64–1.37) 0.90 (0.53–1.48)
>High school 149 (74.1) 628 (71.4) Reference Reference
Income
<$50,000 93 (46.3) 397 (45.1) 1.24 (0.82–1.87) 1.65 (0.95–2.87)
Refused 14 (7.0) 64 (7.3) 1.25 (0.65–2.38) 2.04 (0.87–4.78)
‡$50,000 94 (46.8) 419 (47.6) Reference Reference
Smoking status
Current smoker 30 (14.9) 104 (11.8) 1.19 (0.73–1.95) 0.37 (0.17–0.81)
Former smoker 67 (33.3) 296 (33.6) 1.10 (0.77–1.55) 0.98 (0.61–1.58)
Never smoker 104 (51.7) 480 (54.6) Reference Reference
Radiation
Yes 85 (71.4) 259 (61.5) — 1.74 (1.06–2.87)
No 34 (28.6) 162 (38.5) — Reference
Chemotherapy and endocrine therapy
Both 20 (17.2) 60 (14.3) — 0.52 (0.23–1.17)
Chemotherapy only 17 (14.7) 37 (8.8) — 1.01 (0.43–2.37)
Endocrine therapy only 49 (42.2) 210 (50.1) — 0.55 (0.30–1.01)
No 30 (25.9) 112 (26.7) — Reference
aAdjusted for age, vitality, BMI, race, marital status, education, income, and smoking status. Bold type indicates statistical significance at
p < 0.05.
bAdjusted for age, vitality, BMI, race, marital status, education, income, smoking status, and treatment type. Bold type indicates
statistical significance at p < 0.05.
cPercentages may not sum up to 100% due to rounding.
OR, odds ratio; CI, confidence interval.







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































We are aware of only three studies comparing weight gain
in early-stage breast cancer patients with cancer-free con-
trols. Two previous studies of weight gain after 6 months3
and 6 years10 of follow-up found no significant differences in
weight gain between women with breast cancer and women
without breast cancer. In a cohort study of women with a
family history of breast cancer, breast cancer survivors had
an increased likelihood for ‡5% weight gain over 4 years
of follow-up than controls without breast cancer.11 To our
knowledge, our study is the first to examine differences in
weight gain among EIBC and DCIS patients and controls
without a history of breast cancer. While EIBC patients were
more likely to report ‡5% weight gain compared with con-
trols, the odds of ‡5% weight gain experienced by DCIS
patients over 2-year follow-up was similar to that of controls.
In our study, a higher proportion of African American than
white women were obese at enrollment (54% and 27%, re-
spectively), similar to higher obesity rates observed in black
and Hispanic women compared with white women in the
United States.33 African American women in our study were
less likely to have ‡5% weight gain than white women, which
was observed in the model with all three diagnostic groups,
and this inverse association was statistically significant in the
stratified model that included only EIBC patients. Some, but
not all, studies have reported that nonwhite women from
various racial/ethnic groups were less likely than white wo-
men to gain weight following breast cancer diagnosis and
treatment. A retrospective cohort study of 1,282 long-term
(>5 years) breast cancer survivors treated in Houston, TX
observed that Asian women had a lower risk of ‡5% weight
gain than white women.31 Across the four U.S. sites of the
ENERGY trial, Hispanic women had a lower odds of gaining
‡5% of body weight than non-Hispanic white women after an
average of 2.65 years of follow-up; and in this study, His-
panic women had higher rates of obesity than non-Hispanic
white women.34 Race was not a significant predictor of ‡5%
Table 4. Logistic Regression for the Relationship Between Selected Characteristics
and ‡5% Weight Gain in Postmenopausal Early-Invasive Breast Cancer Patients
Weight gain ‡5% (N = 59) Weight gain <5% (N = 214) OR (95% CI)a
Median (IQR)
Age 61 (56, 68) 62 (56, 69) 0.97 (0.93–1.01)
Vitality 50 (40, 75) 55 (35, 70) 1.00 (0.99–1.02)
N (%)b
BMI
Obese (‡30 kg/m2) 16 (27.1) 80 (37.4) 0.51 (0.23–1.12)
Overweight (25 to <30 kg/m2) 17 (28.8) 73 (34.1) 0.66 (0.31–1.41)
Normal weight (<25 kg/m2) 26 (44.1) 61 (28.5) Reference
Race
African American 6 (10.2) 46 (21.5) 0.26 (0.09–0.77)
White 53 (89.8) 168 (78.5) Reference
Marital status
Married 31 (52.5) 125 (58.4) 0.81 (0.37–1.77)
Not married 28 (47.5) 89 (41.6) Reference
Education
£High school 39 (66.1) 134 (62.6) 0.77 (0.39–1.54)
>High school 20 (33.9) 80 (37.4) Reference
Income
<$50,000 36 (61.0) 111 (51.9) 2.34 (1.03–5.31)
Refused 7 (11.9) 20 (9.4) 2.04 (0.67–6.15)
‡$50,000 16 (27.1) 83 (38.8) Reference
Smoking status
Current smoker 9 (15.3) 31 (14.5) 0.66 (0.24–1.79)
Former smoker 22 (37.3) 68 (31.8) 1.14 (0.59–2.24)
Never smoker 28 (47.5) 115 (53.7) Reference
Radiation
Yes 42 (71.2) 144 (67.3) 1.19 (0.59–2.40)
No 17 (28.8) 70 (32.7) Reference
Chemotherapy
Both 12 (20.7) 40 (18.7) 0.54 (0.18–1.59)
Chemotherapy only 9 (15.5) 23 (10.8) 0.92 (0.29–2.85)
Endocrine therapy only 25 (43.1) 126 (58.9) 0.40 (0.17–0.95)
No 12 (20.7) 25 (11.7) Reference
aAdjusted for age, vitality, BMI, race, marital status, education, income, smoking status, and treatment type. Bold type indicates
statistical significance at p < 0.05.
bPercentages may not sum up to 100% due to rounding.















































weight gain in either the WHEL study or the SUNSHINE
study.7,10 Furthermore, these studies evaluating the rela-
tionship between race and ‡5% weight gain in breast cancer
survivors were conducted with samples of women residing in
southern and southwestern regions of the United States. Re-
sults from our study in the Midwest suggest that further re-
search of racially/ethnically diverse samples in different
regions across the United States may be warranted to identify
possible geographic variation in ‡5% weight gain in specific
groups of breast cancer survivors and explanatory factors
amenable to intervention.
In the stratified model among EIBC patients in our study,
weight gain varied by smoking status; patients who were
current smokers at diagnosis were less likely to experience
‡5% weight gain than patients who had never smoked. These
results contrast with those of the ENERGY trial, in which,
among patients, smoking at diagnosis was associated with a
2.7-fold increased risk for ‡5% weight gain when compared
to never smokers.34 This finding from the ENERGY trial is
similar to our findings among the controls, who were three
times more likely than never smokers to experience ‡5%
weight gain. Due to the small sample of EIBC patients
who were current smokers at time of diagnosis and experi-
enced ‡5% weight gain (n = 9), our results should be inter-
preted with caution. Continued smoking after a breast cancer
diagnosis has been discouraged because of associations
with treatment toxicity, cancer recurrence, and breast cancer
mortality.35,36 If women in our study quit smoking after di-
agnosis in adherence to survivorship recommendations, this
might explain our findings. Previous studies have shown that
smoking cessation is associated with weight gain in wom-
en.37–39 However, we were unable to examine the relation-
ship between postdiagnosis smoking patterns and weight gain
due to limitations of small sample size.
Several studies have examined the relationship between
various treatments and weight gain after breast cancer with
mixed results.7,10,11,34,40–49 We and others have found that
chemotherapy was not an independent predictor of ‡5%
weight gain.10,34 Although we did not observe any significant
relationships between adjuvant radiation and chemotherapy
and weight gain in EIBC patients, we found that endocrine
therapy was inversely associated with ‡5% weight gain in
models that adjusted for these other treatments. Patients with
ER-negative tumors, for whom endocrine therapy is not in-
dicated, have been found to have significant weight gain after
diagnosis.11,30 Although most breast tumors are hormone-
receptor-positive subtypes (about 80% are estrogen- and/or
progesterone-receptor positive),50 women with ER-negative
tumors are at elevated risk of adverse cancer-related out-
comes, which might be true especially for survivors with
significant weight gain. For example, women with ER-negative
tumors who experienced postdiagnosis weight gain were
reported to be at increased risk for subsequent contralateral
breast cancer.30,51
A novel finding of our study is that income was associated
with ‡5% weight gain in postmenopausal EIBC patients.
Lower income (<$50,000) EIBC patients were twice more
likely to report ‡5% weight gain than higher income patients.
A potential mechanism between low-income status and post-
diagnosis weight gain may be environmental stress. Neigh-
borhood environmental factors (i.e., adverse socioeconomic
conditions and the built environment), for example, have
been associated with weight gain among women in the gen-
eral U.S. population.52,53 However, it is unknown whether
neighborhood-level factors influence weight gain in breast
cancer patients in addition to individual-level (e.g., psycho-
social, clinical, and treatment) factors. Further work should
examine the role of environmental factors in weight gain
after breast cancer.
Strengths of our study include the longitudinal study
design, the large samples of women with incident EIBC and
DCIC, and the inclusion of a large, age-matched control
group of women without a breast cancer history. Our diverse
study sample (22% African American and 44% with annual
income <$50,000) allowed for sociodemographic subgroup
comparisons. We collected detailed data about partici-
pants’ sociodemographic, psychosocial, clinical, and treat-
ment characteristics from medical records, which allowed us
to examine relationships between these factors and weight
gain. Nevertheless, our study also has limitations. All partici-
pants were recruited from two academic medical centers, and
one is a National Cancer Institute-designated comprehensive
cancer center; thus, findings may not be generalizable to
patients recruited from community or rural hospitals or from
other regions in the United States. We did not collect in-
formation about diet and physical activity, and therefore,
could not evaluate potential confounding by these factors.
Due to the extensive lack of height and weight information
in the medical record, we relied on self-reported information
for these variables to compute BMI, which can lead to mis-
classification related to social desirability or recall bias.54
Conclusions
EIBC patients, but not DCIS patients, were more likely to
experience ‡5% weight gain after 2-year follow-up compared
with women without a history of breast cancer. Compared
with patients with advanced breast cancer, EIBC patients
have a lower risk of complications, recurrence, and mortali-
ty.1,2 However, their more favorable prognoses may be
hampered by significant postdiagnosis weight gain and obe-
sity,1,55 which seems especially important for patients with
ER-negative tumor subtypes.30,51 Future work should evaluate
the long-term influence of postdiagnosis weight gain on
patients’ health. Also, the biological mechanisms linking
invasive breast cancer to weight gain remain unclear. Further
research is necessary to elucidate modifiable factors affecting
weight gain in this growing population of cancer survivors.
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